Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. - Wikidata - wikimedia - TriplyDB

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

http://www.wikidata.org/entity/Q34530109

about

Anti-angiogenic therapies for metastatic colorectal cancer Systemic coagulation parameters in mice after treatment with vascular targeting agents.Current targeted therapies in the treatment of advanced colorectal cancer: a review Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer Antiangiogenic mechanisms and factors in breast cancer treatment Novel therapeutic agents in the treatment of metastatic colorectal cancer Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis Population pharmacokinetics of bevacizumab in cancer patients with external validation Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials A fresh look at zebrafish from the perspective of cancer research Anti-angiogenic agents in metastatic colorectal cancer Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives Value of bevacizumab in treatment of colorectal cancer: A meta-analysis Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy Is inflammation the cause of pre-eclampsia?Cancer concepts and principles: primer for the interventional oncologist-part II Immunotherapy strategies for multiple myeloma: the present and the future Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer Immunotherapy in human colorectal cancer: Challenges and prospective Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study Incidence and management of bevacizumab-related toxicities in colorectal cancer Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis Core-shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkers Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis Hypertension and maternal-fetal conflict during placental malaria Second-line systemic therapy for metastatic colorectal cancer.Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: An updated meta-analysis of 12 randomized controlled trials.Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents.Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy.Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer.Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data.

P2860

Q24241813-60BB4059-ECA6-4C5C-BB22-7004BDC4EDFB Q25257132-E6061D9E-3AA6-43A1-9296-7F92BF141BFD Q26740067-13674528-6A18-4783-B6A2-14556A604982 Q26746067-49BB8900-99C0-4AA1-9E71-3BAED0A6DBF9 Q26747666-70DDFF94-DDAD-47A0-BB25-9DB7D4B3CC5B Q26748924-226C5CEC-1322-4C4A-A50C-B9C33B86D53E Q26751226-7557C20E-B1DE-42AC-99EA-14A709661D8B Q26769932-E9A2B81B-4015-4A9F-950A-BD03F0D26F24 Q26777704-A371E551-93EE-436F-95F1-69A5950A6B27 Q26779580-22CE35F8-BFBC-4F73-9A41-2E5BA9F7193E Q26786618-C6F18BCC-3413-470C-A4F9-4383D6BA4708 Q26799700-BD25D27C-58AB-44EE-B131-AC31E616A962 Q26801911-6605CBC5-F603-4EC4-9D51-8E22106EC5C8 Q26822395-19F29FEF-520A-4E99-9B77-33CB949F8CE9 Q26824086-109F0B81-5871-4027-8D6F-7AC2509F9CA5 Q26826817-D3438360-6AD3-4B45-925A-B6A2727C2B87 Q26849789-1B2ACBBF-C3AA-43CD-8BE1-7019602738DB Q26853604-08F18127-1DDE-47A4-9988-0395ED48D5D9 Q27007059-94E900D0-ECC4-40FB-8905-D2BF80D05067 Q27010961-EDF5D2CE-345E-4910-BD7B-0B5CA9CCD821 Q27021939-C137262B-D45A-4E4E-9224-83D12BAFCB6E Q28068654-DF69674F-77A8-4B01-B109-3494770D8863 Q28068788-35D83014-950D-4EE4-ABBB-886AA5A974D2 Q28211801-A80B28F2-1AF8-4A7B-9B12-D818DD711989 Q28219069-CAABBC3A-09F6-4C7E-BA6D-56C4F7AAFC25 Q28219257-BD864EB7-46AF-4176-9C74-2C46BA12C539 Q28260997-477BF79E-7B48-4DCC-AA3D-7AF427C746A5 Q28474977-DC4F33D6-413F-4D89-B075-29D982E2BE36 Q28534015-E48663A4-54AF-4341-BFCB-8B5856381180 Q28766797-284F7DA1-CF59-4DCB-923F-AFD125A791FB Q30238760-A67209F3-E163-4357-A69F-707CC1DC526A Q30248296-A4038E83-202B-4DDE-8C9B-DE03F24186C1 Q30249335-1249261A-DB07-430A-8BEB-028563222C51 Q30358961-D4B07D8C-E0A8-44C0-9C02-F6CEA449CF4F Q30422372-497C9B11-153E-4B13-B2AB-61281FC84594 Q30439565-315C06D9-6F1E-4BFB-B201-DAF06CEDF49E Q30441458-25D820D5-5B9A-4CAE-A6B2-53DA8042EFF9 Q30455612-E0F9686E-3A4A-4FFD-ACC9-3839F78E04DF Q30862367-D7DD2E94-76E0-4046-9249-821B908FF1B2 Q30884552-531F7C1D-F68F-48A9-ACB7-E2CCF6D4C57C

P2860

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

http://www.wikidata.org/entity/Q34530109

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Phase II, randomized trial com ...... metastatic colorectal cancer.

@ast

Phase II, randomized trial com ...... metastatic colorectal cancer.

@en

Phase II, randomized trial com ...... metastatic colorectal cancer.

@nl

type

label

Phase II, randomized trial com ...... metastatic colorectal cancer.

@ast

Phase II, randomized trial com ...... metastatic colorectal cancer.

@en

Phase II, randomized trial com ...... metastatic colorectal cancer.

@nl

prefLabel

Phase II, randomized trial com ...... metastatic colorectal cancer.

@ast

Phase II, randomized trial com ...... metastatic colorectal cancer.

@en

Phase II, randomized trial com ...... metastatic colorectal cancer.

@nl

P1433

Q34530109-B9D025A0-D278-42DF-B328-FE22C49F3F49

P1476

Q34530109-BA46F0B6-5162-4E89-B4E8-83E008EC22F1

P2093

Q34530109-2F043338-E3D1-4659-B0B2-10096DB6014F

Q34530109-5E1F7DA6-DD57-4C88-AF74-56CDFF71451D

Q34530109-5F044324-6178-4747-BF3E-A0CB37941592

Q34530109-64E39675-4B73-4CE9-AA56-EC8A92365717

Q34530109-B7D150FF-A065-4371-BE6B-9F77538FA574

Q34530109-B901AB09-EA93-420D-9990-240CE2587360

Q34530109-E73C9189-5A07-4D9D-8817-373D059948B6

Q34530109-FE9C12BB-1F52-4103-8B67-F267F1A9DE66

P304

Q34530109-7CAB8C81-346F-412C-AFE5-5A904DEDC2BE

P31

Q34530109-8D3EFC46-E294-4F34-86AF-A2FFDF02CE20

P356

Q34530109-358E0C77-31A3-4887-B58F-B0C4A843F0A8

P407

Q34530109-5B378261-6678-49C1-8ACB-ECA1ED63BE0F

P433

Q34530109-0C1E20CC-C91B-4D1C-BDB8-414C84B76034

P478

Q34530109-D332288B-D5F1-4E9B-9BC6-56CD54111ECF

P577

Q34530109-F930C76D-D96A-45A4-872D-4EA1A70099E6

P698

Q34530109-F4A46456-129E-47DA-867E-C3B0DA1EEB9B

P921

Q34530109-39C27144-8E0E-4F05-A502-FEC7EC6C7887

Q34530109-4CA98FD0-4222-457E-B651-D71194DA99EE

Q34530109-4EE70C8A-EA75-4C25-AB1B-1FCA568C10F9

Q34530109-D2EE9734-A112-429D-9EFA-24734F08C949

P356

JCO.2003.10.066

P1433

Journal of Clinical Oncology

P1476

Phase II, randomized trial com ...... metastatic colorectal cancer.

@en

P2093

Emily Bergsland

http://www.w3.org/2001/XMLSchema#string

Fairooz Kabbinavar

http://www.w3.org/2001/XMLSchema#string

Grazyna Lieberman

http://www.w3.org/2001/XMLSchema#string

Herbert I Hurwitz

http://www.w3.org/2001/XMLSchema#string

Louis Fehrenbacher

http://www.w3.org/2001/XMLSchema#string

Neal J Meropol

http://www.w3.org/2001/XMLSchema#string

Susan Griffing

http://www.w3.org/2001/XMLSchema#string

William F Novotny

http://www.w3.org/2001/XMLSchema#string

P304

60-65

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2003.10.066

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2003-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12506171

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

phase II clinical trial